Company intelligence / Profile preview
Protagenic Therapeutics, Inc.
New York, New York, United Statesprotagenic.com ↗
- Ownership
- Public · PTIX
- Employees
- ~3
- Development stage
- Phase 1
01
Overview
Protagenic’s lead program PT00114 has completed preclinical pharmacology and enabling studies. The company plans its first human clinical trial in collaboration with Harvard/Massachusetts General Hospital targeting major depressive disorder and related indications. No published human efficacy results as of May 2025
- Therapeutic areas
- Psychiatry
- Modalities
- Peptides
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Collaboration with Harvard/Massachusetts General Hospital for initial clinical studies
04
Financials
- Market cap
- $1.1M
- Total revenue
- $0
- Enterprise value
- $574.4K
Beyond the preview
Go deeper on Protagenic Therapeutics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Protagenic Therapeutics, Inc..